

JENKINS
WILSON
& TAYLOR

patent attorneys

December 5, 2003



RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

E. ERIC MILLS

BENTLEY J. OLIVE

MICHAEL J. CROWLEY

*CHRIS PERKINS, PH.D.

**JAMES DALY IV, PH.D.

JEFFREY CHILDERS, PH.D.

OF COUNSEL
SOROJINI BISWAS

*LICENSED ONLY IN CA

**LICENSED ONLY IN KY

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 5, 2003.

Gayle W. Chaney
Gayle W. Chaney
Date of Signature: 12-5-03

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/613,262
for ANGIO-IMMUNOTHERAPY
Our Ref. No. 1430/13

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (1 page) in duplicate;
3. Copies of cited references (4 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Although no fee is believed to be due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.
Registration No. 39,395

AAT/gwc

Enclosures

Customer No. 25297

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 5, 2003.

PATENT



Gayle W. Chaney
Date of Signature

12-5-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gilboa et al.

Group Art Unit: Not Assigned

Serial No.: **10/613,262**

Examiner: Not Assigned

Filed: July 3, 2003

Docket No.: 1430/13

Confirmation No.:

For: ANGIO-IMMUNOTHERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Applicant hereby certifies that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Early passage of the subject application to issue is earnestly solicited.


Appln. No.: 10/613,262

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 12/5/2003

By: 
Arles A. Taylor, Jr.
Registration No. 39,395

AAT/gwc

Enclosures

Customer No. 25297

**FORM PTO-1449** U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No. 1430/13

Serial No.
10/613,262

List of Documents Cited by Applicant

Applicant(s): Gilboa et al.

Filing Date: July 3, 2003

Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
	1.	2003/0113919A1	06/19/2003	Emtage et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	2.	Crystal, R.G., "In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors," <u>Cancer Chemother. Pharmacol.</u> , Vol. 43 (suppl), pp. S90-S99 (1999).
	3.	Machein et al., "Antiangiogenic Gene Therapy in a Rat Glioma Model Using a Dominant-Negative Vascular Endothelial Growth Factor Receptor 2," <u>Human Gene Therapy</u> , Vol. 10, pp. 1117-1128 (1999).
	4.	Niederman et al., "Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors," <u>Proc. Natl. Acad. Sci.</u> , Vol. 99, No. 10, pp. 7009-7014 (May 2002).

EXAMINER _____

DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.